Evaluation of fibrinolytic therapy by measuring cross-linked fibrin derivatives and plasmin-.ALPHA.2-plasmin inhibitor complex in plasma

HOYU TAKAHASHI, SHIN-ICHIRO TAKIZAWA, MASAHARU HANANO, WATARU TATEWAKI, YASUKO NAGASAKI, YASUO SASAGAWA, AKIRA SHIBATA
1987 Tohoku journal of experimental medicine  
Plasma levels of a2-plasmin inhibitor (a2PI), plasmin-a2PI complex and cross-linked fibrin derivatives (XDP) were measured in 8 patients (12 episodes) with thromboembolic disorders on the initial administration of urokinase. In conjunction with a decrease in plasma a2PI activity and antigen, plasmin-a2PI complex increased following urokinase infusion in all cases except one who received a low dose (60,000 units) of urokinase. However, changes in XDP were variable among the patients. Plasma XDP
more » ... tients. Plasma XDP level increased markedly in one, moderately in 4, slightly in one, and remained unchanged in 6 cases (episodes). The increment of plasma XDP correlated (r = 0.804, p -0.003) with the dose of urokinase administered, but was independent of changes in plasmin-a2PI complex. The plasma XDP elevation was associated with clinical improvement. These results suggest that simultaneous measurements of XDP and plasmin-a2 PI complex in plasma would be valuable for the pharmacological or hemostatic assessment of thrombolytic therapy. fibrinolytic therapy ; urokinase ; cross-linked fibrin derivatives ; plasmin-a2plasmin inhibitor complex ; a2-plasmin inhibitor
doi:10.1620/tjem.153.295 pmid:2964745 fatcat:wmsxbnbqknfetjdbp73dkndcym